Seres therapeutics announces further constructive feedback from fda on ser-155 phase 2 study protocol and implements cost reduction actions to extend cash runway

Following recent constructive fda feedback, seres anticipates finalizing ser-155 phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies
MCRB Ratings Summary
MCRB Quant Ranking